Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma.We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ≥2×106 CD34+cells/kg, 80% of them at least 5×106 CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.
- CD34+ collection
- Diffuse large B-cell lymphoma
- Stem cell mobilization
ASJC Scopus subject areas